What is Deargen?
Founded in 2016, Deargen specializes in the application of advanced artificial intelligence to the drug discovery and development lifecycle. The company's core competencies include the prediction of biomarkers, the identification of disease targets, and the extraction of viable candidate substances for new drug development. By utilizing meta-analysis of genome big data, Deargen provides a robust in-silico framework that significantly reduces the time and cost associated with traditional pharmaceutical research.
The company's market position is bolstered by its proven track record, including the early prediction of remdesivir as a potential COVID-19 treatment. This capability, combined with its success in prestigious deep-learning challenges like ILSVRC and the Dream Challenge, establishes Deargen as a high-authority entity in the intersection of computational biology and clinical pharmacology. Their collaborative model with established pharmaceutical firms further validates their technology as a critical component of the modern drug development pipeline.
How much funding has Deargen raised?
Deargen has raised a total of $17M across 1 funding round:
Series B
$17M
Series B (2022): $17M with participation from Korea Development Bank and The Wells Investment
Key Investors in Deargen
Korea Development Bank
A state-owned policy development bank in South Korea that provides essential capital and management support to foster the growth of strategic industrial projects.
The Wells Investment
A South Korean investment firm specializing in bio-healthcare and deep tech, providing capital and management expertise to high-growth, innovative enterprises.
What's next for Deargen?
With the infusion of this latest capital, Deargen is poised to transition into a more aggressive phase of commercialization and strategic expansion. The company is expected to prioritize the enhancement of its proprietary AI engines, focusing on increasing the precision of its in-silico predictions to support a broader portfolio of therapeutic assets. Furthermore, the firm will likely seek to deepen its existing partnerships with global pharmaceutical institutions, leveraging its technological edge to streamline the path from target identification to clinical trials.
As the bio-healthcare industry increasingly pivots toward data-centric methodologies, Deargen's focus on scalable, AI-driven solutions positions it to capture significant market share. The strategic deployment of these funds will be instrumental in maintaining the company's competitive advantage, ensuring that its research capabilities remain at the forefront of the global effort to modernize drug discovery through machine learning and big data analytics.
